For instance, YERVOY, a human CTLA-4 blocking antibody, is recommended as first-line treatment for metastatic or recurrent NSCLC adult patients with no EGFR or ALK aberrations in combination with nivolumab and platinum-doublet chemotherapy (2 cycles). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.